ZURICH (Reuters) - Swiss drugmaker Roche will be able to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from rivals' copies through its new medicines, Chief Executive Severin Schwan said on Tuesday.
WARSAW/LONDON (Reuters) - The European Bank for Reconstruction and Development (EBRD) said on Tuesday it has issued its first "health bond", raising 317 million zlotys ($92.84 million) from one of Japan's largest life insurers to finance health projects across the globe.
CHICAGO (Reuters) - The U.S. Department of Agriculture scrapped proposed rules on Monday that for the first time would have mandated specific space requirements for hens laying organic eggs and spelled out what it means for the birds to have access to the outdoors.
BOSTON (Reuters) - A federal judge on Monday rejected a lawsuit by Massachusetts' attorney general challenging new rules by President Donald Trump's administration that make it easier for employers to avoid providing insurance that covers women's birth control.
BOSTON (Reuters) - Impax Laboratories Inc went to trial on Monday over allegations by major retailers and consumers that the company agreed to delay launching a generic version of acne medication Solodyn in exchange for millions of dollars from the manufacturer.
(Reuters Health) - Nearly all the adolescents in an economically disadvantaged, largely minority population in San Francisco who were tested for a tobacco-smoke byproduct showed evidence of regular exposure, a small study found.
BRUSSELS (Reuters) - Europe's drinks sector announced plans on Monday to inform consumers more about the energy content and ingredients in beer, wine and spirits in a self-policing move, but critics said much of this information would only be available online.
(Reuters Health) - Participation in high school football has been steadily falling in recent years amid mounting concerns about the potential for traumatic brain injuries to lead to lasting health problems, a U.S. study suggests.
PARIS (Reuters) - Mexico reported two outbreaks of highly pathogenic H7N3 bird flu virus in the central part of the country, of which one at chicken farm, the World Organisation for Animal Health said on Monday, citing a Mexican agriculture ministry report.
BOSTON (Reuters) - Impax Laboratories Inc went to trial on Monday over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication's manufacturer.
(Reuters) - Anthera Pharmaceuticals Inc said on Monday it would evaluate all strategic options after its lead drug failed in a late-stage trial, sending its shares down 80 percent in premarket trading.
(Reuters) - Biogen Inc said on Monday it would buy Pfizer Inc's experimental treatment for a symptom associated with schizophrenia in a deal that could near $600 million and mark its foray into the emerging market for neuropsychiatry.
(Reuters) - GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug.
(Reuters) - Hikma Pharmaceuticals Plc said on Monday it plans a new clinical study on its generic version of GlaxoSmithKline's popular lung drug Advair, as it looks to resolve an ongoing dispute with the Food and Drug Administration over plans to launch the drug in the U.S.
LONDON, (Reuters) – - They can make test-tube babies, grow human eggs in a lab and reproduce mice from frozen testicle tissue, but when it comes to knowing how a man's sperm can swim to, find and fertilize an egg, scientists are still floundering.
JOHANNESBURG (Reuters) - South African gold producers will likely reach a settlement within six weeks in a lawsuit over a fatal lung disease that companies have set aside 5 billion rand ($420 million) in provisions for, a lawyer and industry group said on Sunday.
(Reuters) - A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine.